Astrazeneca PLC (AZN) Financials
AZN Assets vs Liabilities
| Date | Assets | Liabilities |
|---|---|---|
| 2023-12-31 | 101.1 billion | 62.0 billion |
| 2023-09-30 | 96.1 billion | 58.9 billion |
| 2023-06-30 | 96.5 billion | 59.1 billion |
| 2023-03-31 | 96.7 billion | 60.9 billion |
AZN Free Cash Flow and Stock based compensation
| Date | Free Cash Flow | Stock based compensation |
|---|---|---|
| 2023-12-31 | 1.4 billion | ? |
| 2023-09-30 | 2.2 billion | ? |
| 2023-06-30 | 1.2 billion | ? |
| 2023-03-31 | 1.7 billion | ? |
AZN Net Income
| Date | Net Income |
|---|---|
| 2023-12-31 | 897.0 million |
| 2023-09-30 | 1.7 billion |
| 2023-06-30 | 2.1 billion |
| 2023-03-31 | 2.3 billion |
AZN Cash and Debt
| Date | Cash | Debt | Capital Lease |
|---|---|---|---|
| 2023-12-31 | 5.9 billion | - | 1.1 billion |
| 2023-09-30 | 5.1 billion | - | 979.0 million |
| 2023-06-30 | 5.8 billion | - | 953.0 million |
| 2023-03-31 | 6.5 billion | - | 962.0 million |
AZN Shares Outstanding
AZN Expenses
| Date | Capex | R&D | G&A | S&M |
|---|---|---|---|---|
| 2023-12-31 | 946.0 million | 3.1 billion | 13.8 billion | 17.8 billion |
| 2023-09-30 | 879.0 million | 2.6 billion | 4.8 billion | 4.9 billion |
| 2023-06-30 | 483.0 million | 2.7 billion | 5.0 billion | 5.1 billion |
| 2023-03-31 | 1.5 billion | 2.6 billion | 4.1 billion | 4.2 billion |
AZN Cost of Revenue
| Date | Revenue | Cost of Revenue |
|---|---|---|
| 2023-12-31 | 12.0 billion | 2.3 billion |
| 2023-09-30 | 11.5 billion | 2.1 billion |
| 2023-06-30 | 11.4 billion | 2.0 billion |
| 2023-03-31 | 10.9 billion | 1.9 billion |
AZN
Price: $75.17
Dividend Yield: 0.04%
Forward Dividend Yield: 2.62%
Payout Ratio: 104.23%
Dividend Per Share: 1.97 USD
Earnings Per Share: 1.90 USD
P/E Ratio: 35.25
Exchange: NMS
Sector: Healthcare
Industry: Drug Manufacturers - General
Volume: 4.8 million
Ebitda: 1.8 billionMarket Capitalization: 207.1 billion
Average Dividend Frequency: 2
Years Paying Dividends: 32
DGR3: 1.18%
DGR5: 1.14%
DGR10: 8.24%
DGR20: 11.80%